Accessibility settings

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/58031, first published .
Frustrated boy with headphones playing video games in a bedroom

Clozapine for Treatment-Resistant Disruptive Behaviors in Youths With Autism Spectrum Disorder Aged 10-17 Years: Protocol for an Open-Label Trial

Clozapine for Treatment-Resistant Disruptive Behaviors in Youths With Autism Spectrum Disorder Aged 10-17 Years: Protocol for an Open-Label Trial

Journals

  1. Al-Wahaibi L, Abou-Zied H, Mahmoud M, Youssif B, Bräse S, Rabea S. Design, synthesis, and antiproliferative activity of new 5-ethylsulfonyl-indazole-3-carbohydrazides as dual EGFR/VEGFR-2 kinases inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2025;40(1) View
  2. Wei J, Dong T. The Effect of Clozapine on Immune‐Related Biomarkers in Schizophrenia Patients. Journal of Biochemical and Molecular Toxicology 2025;39(9) View
  3. Greydanus D, Azeem M, AlMuraikhi M, Nazeer A. Challenging behaviors in adolescents with intellectual and developmental disabilities: current pharmacological perspectives. Current Opinion in Psychiatry 2026;39(2):109 View
  4. da Rosa A, Sorato G, Manjabosco F, Dellazari L, de Bem É, Falcão A, Cia L, Nedel A, da Costa M, Bezerra O, Borges R, Rohde L, Graeff-Martins A. Clozapine for Severe Treatment-Resistant Disruptive Behaviors in Youth with Autism Spectrum Disorder: A Prospective Real-World Interventional Study. Journal of Child and Adolescent Psychopharmacology 2026 View